Navigation Links
Ascenta Therapeutics Announces Multiple Presentations on AT-101 at 2009 ASCO Annual Meeting
Date:5/26/2009

MALVERN, Pa., May 26 /PRNewswire/ -- Ascenta Therapeutics announced today that eleven presentations or publications on pre-clinical and clinical studies of AT-101, an oral, pan-Bcl-2 inhibitor, in several major tumor types will be made during the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting, May 29-June 2, in Orlando, Florida. Abstracts are available at www.asco.org.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090227/PH75873LOGO )

Prostate Cancer

MacVicar G, et al. An open-label, multicenter, phase I/II study of AT-101 in combination with docetaxel (D) and prednisone (P) in men with castrate resistant prostate cancer (CRPC). Abstract #5062; Poster Board #17; Poster Discussion, May 31, 8:00 a.m.-12:00 p.m.

Poiesz B, et al. Preliminary report of an open-label, multicenter, phase I/II study of AT-101 in combination with docetaxel (D) and prednisone (P) in men with docetaxel refractory prostate cancer. Abstract #5145; Poster Board #J13; GU General Poster Session, May 31, 2:00 p.m.-6:00 p.m.

Glioma

Fiveash J, et al. NABT-0702: A phase II study of AT-101 in recurrent glioblastoma multiforme (GBM). Abstract #2010; Poster Board #2; Poster Discussion, May 30, 8:00 a.m.-12:00 p.m.

Lung Cancer

Heist R, et al. A phase I/II study of AT-101 in combination with topotecan (T) in patients with relapsed or refractory small cell lung cancer (SCLC) after prior platinum containing first line chemotherapy. Abstract #8106; Poster Board #R14; Lung Cancer - Metastatic, May 30, 2:00 p.m.-6:00 p.m.

Ready N, et al. AT-101 or placebo (P) with docetaxel (D) in second line NSCLC with gene signature biomarker development. Abstract #3577; Poster Board #J19; Developmental Therapeutics, May 30, 8:00 a.m.-12:00 p.m.

Min P, et al. Small molecule pan-bcl-2 inhibitor AT-101 induces apoptosis in NSCLC by upregulating noxa and enhances antitumor activity of docetaxel or targeted kinase inhibitors. Abstract #e14591; Publication only.

Non-Hodgkin's Lymphoma

Kingsley E, et al. An open-label, multicenter, phase II study of AT-101 in combination with rituximab (R) in patients with untreated, grade I-II, follicular Non-Hodgkin's Lymphoma (FL). Abstract #8582; Poster Board #S11; Lymphoma and Plasma Cell Disorders, May 30, 8:00 a.m.-12:00 p.m.

Advanced Cancers

Leal TB, et al. A phase I study of AT-101 in combination with cisplatin (P) and etoposide (E) in patients with advanced solid tumors and extensive-stage small cell lung cancer (ES-SCLC). Abstract #e13502; Publication only.

Saleh M, et al. Extended phase I trial of the oral pan-Bcl-2 inhibitor AT-101 by multiple dosing schedules in patients with advanced cancers. Abstract #e14537; Publication only.

Mechanism of Action/Pharmacokinetics

Wang S, et al. AT-101 induces transcriptional up-regulation of Noxa and Puma and overcomes Mcl-1-mediated cancer cell resistance to apoptosis. Abstract # e14611; Publication only.

Pitot H, et al. Analysis of a phase I pharmacokinetic (PK)/food effect study of AT-101 in patients with advanced solid tumors. Abstract #2557; Poster Board #B18; Developmental Therapeutics, May 30, 8:00 a.m.-12:00 p.m.

About AT-101

AT-101 is an orally-active, pan-Bcl-2 inhibitor (including Bcl-2, Bcl-xL, Bcl-w, and Mcl-1 inhibition) that has been shown to induce apoptosis directly by operating as a BH3 mimetic and indirectly as an independent upregulator of Noxa and Puma. By blocking the binding of Bcl-2 family members with proapoptotic proteins and upregulating specific proapoptotic factors, AT-101 lowers the threshold for cancer cells to undergo apoptosis in various tumor types. In Phase I and Phase II trials, AT-101 has demonstrated single-agent cytoreductive activity in several cancers, including chronic lymphocytic leukemia (CLL), non-Hodgkins lymphoma (NHL), and prostate cancer. Phase II combination trials are ongoing in several cancers, including hormone-refractory prostate cancer and non-small cell lung cancer (with Taxotere(R)), B-cell malignancies (with Rituxan(R)), small cell lung cancer (with Hycamtin(R)), glioma (with Temodar(R), +/- chemoradiotherapy [XRT]) and esophageal cancer (with docetaxel, 5-fluorouracil and XRT).

About Ascenta Therapeutics

Ascenta Therapeutics, Inc. is a privately-held, clinical-stage biopharmaceutical company that discovers and develops new medicines for the treatment of cancer. The company is headquartered in Malvern, Pennsylvania, and has a preclinical research facility in Shanghai, China. Its technology, licensed from both the National Institutes of Health and the laboratory of Dr. Shaomeng Wang at the University of Michigan, is focused on discovering molecules that restore the natural potential for cancer cells to undergo cell death (apoptosis). Ascenta's lead agent, AT-101, is an orally-active small molecule pan Bcl-2 inhibitor (Bcl-2, Bcl-xL, and Mcl-1) currently in Phase 2 clinical trials in castrate resistant prostate cancer. The Company's preclinical pipeline includes the oral multi-IAP antagonist AT-406, and an HDM2-p53 inhibitor program.

For additional information on Ascenta Therapeutics, please visit the company's website at www.ascenta.com


'/>"/>
SOURCE Ascenta Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Ascenta Therapeutics Announces Positive Preliminary Results with AT-101 in Docetaxel Refractory Prostate Cancer
2. Oxford BioTherapeutics and GlaxoSmithKline Form Strategic Alliance to Develop Novel Cancer Therapeutic Antibodies
3. FDA Accepts Arno Therapeutics IND for AR-12 a PDK1 Inhibitor That Blocks the PI3K/Akt Pathway
4. Logical Therapeutics Appoints Peter A. Lankau as CEO and Director
5. Arcion Therapeutics Topical Pain Candidate, ARC-4558, Significantly Reduces Pain Caused by Diabetic Neuropathy
6. Trius Therapeutics Announces Presentations Featuring Torezolid Antibiotic at the 19th European Congress of Clinical Microbiology and Infectious Diseases
7. Hyperion Therapeutics Receives Orphan Drug Designation for HPN-100 for the Treatment of Urea Cycle Disorders
8. Sirion Therapeutics Announces Clinical Data Presentations at the 2009 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
9. Intarcia Therapeutics, Inc. Announces Completion of Enrollment of ITCA 650 Phase 1b Study for the Treatment of Type 2 Diabetes
10. Hyperion Therapeutics Announces Results for Phase II Study in Urea Cycle Disorders
11. Amicus Therapeutics Announces Issuance of New Plicera(TM) Composition of Matter Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... FRANCISCO , February 28, 2017 The global  pulse ... a new report by Grand View Research, Inc. The pulse oximeters market is ... to the growing prevalence of target diseases such as chronic obstructive pulmonary disease ... Continue Reading ... Grand View Research ...
(Date:2/28/2017)... , Feb 28, 2017 Nordic Nanovector ASA (OSE: ... 2016. A presentation of the results by the company,s senior management ... Oslo - details below. ... 2016 was a very successful year for ... development of Betalutin®, progressed with our preclinical candidates and build the ...
(Date:2/27/2017)... Ga., Feb. 27, 2017 Halyard Health, Inc. (NYSE: ... 2016 results and provided its 2017 outlook and related key ... sales were $410 million, a 2 percent increase compared to ... fourth quarter 2016 was $10 million compared to net income ... quarter adjusted net income was $24 million compared to adjusted ...
Breaking Medicine Technology:
(Date:2/28/2017)... ... February 28, 2017 , ... BrightStar Care Marietta announced that it has received ... Pulse. This award is granted only to top-ranking home care providers, based on client ... ranked among home care providers from across the country who have proven their ability ...
(Date:2/27/2017)... (PRWEB) , ... February 27, 2017 , ... ... mass and overall body strength, which often leads to a host of health ... Journal of the American Geriatrics Society discovered that good overall muscle strength ...
(Date:2/27/2017)... (PRWEB) , ... February 27, 2017 , ... Much attention ... concern for women who become dependent on opioid painkillers has fallen short. From 1999 ... compared to a 237% increase in fatal overdoses in male populations.(1) , The proportion ...
(Date:2/27/2017)... ... February 27, 2017 , ... This webinar , sponsored ... a tool to characterize particle size distributions in the field of geoscience and ... novel scientific findings. It describes methods of optimized and standardized sample collection, preparation ...
(Date:2/27/2017)... Vancouver, BC (PRWEB) , ... February 27, 2017 ... ... top drug rehabilitation and alcohol treatment programs in British Columbia, Canada, at ... (RMT) to its team. The new hire, Mackenzie Alsager, showcases the Centre's commitment ...
Breaking Medicine News(10 mins):